Io Biotech Stock Cash And Equivalents

IOBT Stock

USD 0.96 0.01 1.05%

IO Biotech fundamentals help investors to digest information that contributes to IO Biotech's financial success or failures. It also enables traders to predict the movement of IOBT Stock. The fundamental analysis module provides a way to measure IO Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IO Biotech stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

IO Biotech Company Cash And Equivalents Analysis

IO Biotech's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current IO Biotech Cash And Equivalents

170.12 M

Most of IO Biotech's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IO Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

IOBT Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for IO Biotech is extremely important. It helps to project a fair market value of IOBT Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since IO Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of IO Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of IO Biotech's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Capital Surpluse
Total Assets		1.0	1.0	-0.38	-0.99	-0.83	0.97	0.43	-0.97	1.0	-0.38	1.0	0.6	1.0	-0.84	0.6	0.72	-0.38
Total Stockholder Equity	1.0		1.0	-0.37	-0.99	-0.83	0.98	0.43	-0.97	1.0	-0.37	1.0	0.59	1.0	-0.82	0.59	0.72	-0.37
Net Tangible Assets	1.0	1.0		-0.34	-0.98	-0.83	0.98	0.42	-0.97	1.0	-0.34	1.0	0.6	1.0	-0.82	0.6	0.73	-0.34
Current Deferred Revenue	-0.38	-0.37	-0.34		0.42	0.61	-0.41	0.25	0.41	-0.36	1.0	-0.38	-0.44	-0.38	0.48	-0.44	-0.46	1.0
Net Debt	-0.99	-0.99	-0.98	0.42		0.83	-0.95	-0.47	0.96	-0.99	0.42	-0.99	-0.53	-0.99	0.85	-0.53	-0.68	0.42
Retained Earnings	-0.83	-0.83	-0.83	0.61	0.83		-0.9	0.06	0.83	-0.82	0.61	-0.83	-0.81	-0.82	0.84	-0.81	-0.93	0.61
Accounts Payable	0.97	0.98	0.98	-0.41	-0.95	-0.9		0.24	-0.97	0.97	-0.41	0.97	0.7	0.96	-0.81	0.7	0.85	-0.41
Net Receivables	0.43	0.43	0.42	0.25	-0.47	0.06	0.24		-0.35	0.43	0.25	0.43	-0.38	0.46	-0.34	-0.38	-0.21	0.25
Total Liab	-0.97	-0.97	-0.97	0.41	0.96	0.83	-0.97	-0.35		-0.98	0.41	-0.97	-0.54	-0.96	0.74	-0.54	-0.74	0.41
Net Invested Capital	1.0	1.0	1.0	-0.36	-0.99	-0.82	0.97	0.43	-0.98		-0.36	1.0	0.58	1.0	-0.81	0.58	0.71	-0.36
Short Long Term Debt	-0.38	-0.37	-0.34	1.0	0.42	0.61	-0.41	0.25	0.41	-0.36		-0.38	-0.44	-0.38	0.48	-0.44	-0.46	1.0
Total Current Assets	1.0	1.0	1.0	-0.38	-0.99	-0.83	0.97	0.43	-0.97	1.0	-0.38		0.59	1.0	-0.83	0.59	0.71	-0.38
Capital Stock	0.6	0.59	0.6	-0.44	-0.53	-0.81	0.7	-0.38	-0.54	0.58	-0.44	0.59		0.57	-0.58	1.0	0.82	-0.44
Net Working Capital	1.0	1.0	1.0	-0.38	-0.99	-0.82	0.96	0.46	-0.96	1.0	-0.38	1.0	0.57		-0.84	0.57	0.7	-0.38
Short Term Debt	-0.84	-0.82	-0.82	0.48	0.85	0.84	-0.81	-0.34	0.74	-0.81	0.48	-0.83	-0.58	-0.84		-0.58	-0.73	0.48
Common Stock	0.6	0.59	0.6	-0.44	-0.53	-0.81	0.7	-0.38	-0.54	0.58	-0.44	0.59	1.0	0.57	-0.58		0.82	-0.44
Property Plant Equipment	0.72	0.72	0.73	-0.46	-0.68	-0.93	0.85	-0.21	-0.74	0.71	-0.46	0.71	0.82	0.7	-0.73	0.82		-0.46
Capital Surpluse	-0.38	-0.37	-0.34	1.0	0.42	0.61	-0.41	0.25	0.41	-0.36	1.0	-0.38	-0.44	-0.38	0.48	-0.44	-0.46

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict IO Biotech

In accordance with the recently published financial statements, IO Biotech has 170.12 M in Cash And Equivalents. This is 79.28% lower than that of the Biotechnology sector and 61.95% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 93.7% higher than that of the company.

IOBT Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IO Biotech's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IO Biotech could also be used in its relative valuation, which is a method of valuing IO Biotech by comparing valuation metrics of similar companies.

IO Biotech is currently under evaluation in cash and equivalents category among its peers.

IOBT Fundamentals

	Return On Equity	-0.78
	Return On Asset	-0.46
	Current Valuation	(14.93 M)
	Shares Outstanding	65.88 M
	Shares Owned By Insiders	0.29 %
	Shares Owned By Institutions	67.40 %
	Number Of Shares Shorted	24.27 K
	Price To Book	0.87 X
	EBITDA	(91.23 M)
	Net Income	(86.08 M)
	Cash And Equivalents	170.12 M
	Cash Per Share	5.90 X
	Total Debt	2.49 M
	Debt To Equity	0.01 %
	Current Ratio	20.94 X
	Book Value Per Share	1.10 X
	Cash Flow From Operations	(71.74 M)
	Short Ratio	0.27 X
	Earnings Per Share	(1.29) X
	Target Price	9.0
	Number Of Employees	78
	Beta	0.22
	Market Capitalization	63.23 M
	Total Asset	150.72 M
	Retained Earnings	(263.82 M)
	Working Capital	131.54 M
	Net Asset	150.72 M

About IO Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze IO Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IO Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IO Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC